Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin

Open access

Abstract

Significance: Age-related bioenergetic insufficiency increases the vulnerability of retinal ganglion cells to intraocular pressure during glaucoma pathogenesis. This paper addresses these relationships and provides a deeper understanding of this common neurodegeneration. We demonstrate an intraocular pressure-dependent decline in retinal pyruvate levels coupled to dysregulated glucose metabolism, and detected mTOR activation at the mechanistic nexus of neurodegeneration and metabolism. Supporting this, oral supplementation of pyruvate or mTOR inhibition by rapamycin strongly protects from neurodegeneration. Bioenergetic enhancement thus provides a readily clinically translatable strategy for neurodegenerative disease. This study provides important avenues for neuroprotection against glaucoma by targeting key metabolic pathways that may be mirrored in other neurodegenerative diseases in which metabolic dysregulation may play a key role.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2014213117

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Pyruvate protects from glaucomatous neurodegeneration in chronic mouse and rat models. (A–I) DBA/2J mice. (A) Retinal pyruvate levels decline following the onset of elevated IOP and are recovered by oral pyruvate treatment (n > 24/group). (B and H) Pyruvate intervention protected from optic nerve degeneration as assessed by PPD staining (paraphenylenediamine; a sensitive stain for damaged axons) in D2 mice (n = 60/group). Green, no or early damage (<5% axon loss; no or early [NOE]); yellow, moderate damage (∼30% axon loss [MOD]); red, severe (>50% axon loss [SEV]) damage. (C) Counts and (D) optic nerve areas from D2 mice demonstrate a robust axon protection by pyruvate treatment (control = no glaucoma, D2-Gpnmb+; n = 10/group; all NOE except for D2 which are SEV). (E and H) Pyruvate protected from RGC soma loss (RBPMS is a specific marker of RGCs in the retina; control = D2. Gpnmb+; n = 6/group). (F and G) Pyruvate rescued PERG amplitude so that 12-mo-old treated mice were not significantly different from 9-mo-old untreated mice that had not yet developed glaucomatous degeneration (PERG is a sensitive measure of RGC function in animals and humans; n > 20/group). Individual example tracings are shown in G. (I) Pyruvate protects from the loss of anterograde axoplasmic transport as assessed by CT-β tracing to the dLGN (dorsal lateral geniculate nucleus) and SC (superior colliculus) (control = D2-Gpnmb+; n = 6/group; quantification shown to the Right). (J–O) Inducible rat model. (J) Laser photocoagulation of limbal blood vessels in rats caused a subacute elevation of IOP (ocular hypertension [OHT]). The magnitude of IOP elevation is unchanged by pyruvate treatment. (K and L) Pyruvate treatment in the rat prevents RGC soma loss and axon loss in the optic nerve. Examples are shown in O. Brn3a is a specific marker of RGCs in the rat retina. (M–O) Pyruvate treatment decreases RGC axon cytoskeletal damage (SMI32+ dystrophic axons) and decreases microglia activation (ED1+ microglia) (n = 18/group for J–O). *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.
Fig. 1. Pyruvate protects from glaucomatous neurodegeneration in chronic mouse and rat models. (A–I) DBA/2J mice. (A) Retinal pyruvate levels decline following the onset of elevated IOP and are recovered by oral pyruvate treatment (n > 24/group). (B and H) Pyruvate intervention protected from optic nerve degeneration as assessed by PPD staining (paraphenylenediamine; a sensitive stain for damaged axons) in D2 mice (n = 60/group). Green, no or early damage (<5% axon loss; no or early [NOE]); yellow, moderate damage (∼30% axon loss [MOD]); red, severe (>50% axon loss [SEV]) damage. (C) Counts and (D) optic nerve areas from D2 mice demonstrate a robust axon protection by pyruvate treatment (control = no glaucoma, D2-Gpnmb+; n = 10/group; all NOE except for D2 which are SEV). (E and H) Pyruvate protected from RGC soma loss (RBPMS is a specific marker of RGCs in the retina; control = D2. Gpnmb+; n = 6/group). (F and G) Pyruvate rescued PERG amplitude so that 12-mo-old treated mice were not significantly different from 9-mo-old untreated mice that had not yet developed glaucomatous degeneration (PERG is a sensitive measure of RGC function in animals and humans; n > 20/group). Individual example tracings are shown in G. (I) Pyruvate protects from the loss of anterograde axoplasmic transport as assessed by CT-β tracing to the dLGN (dorsal lateral geniculate nucleus) and SC (superior colliculus) (control = D2-Gpnmb+; n = 6/group; quantification shown to the Right). (J–O) Inducible rat model. (J) Laser photocoagulation of limbal blood vessels in rats caused a subacute elevation of IOP (ocular hypertension [OHT]). The magnitude of IOP elevation is unchanged by pyruvate treatment. (K and L) Pyruvate treatment in the rat prevents RGC soma loss and axon loss in the optic nerve. Examples are shown in O. Brn3a is a specific marker of RGCs in the rat retina. (M–O) Pyruvate treatment decreases RGC axon cytoskeletal damage (SMI32+ dystrophic axons) and decreases microglia activation (ED1+ microglia) (n = 18/group for J–O). *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.CC BY-NC-ND · PubMed Central
Fig. 2. Retinal metabolic dysfunction occurs early following the onset of elevated IOP in D2 mice. (A) Whole retina samples underwent metabolomic profiling (at 9 mo of age, n = 10/group, control = D2-Gpnmb+, glaucoma = D2). Hierarchical clustering (HC) (Spearman’s) defined metabolically distinct groups. (B and C) A total of 86 metabolites were conclusively identified with level 1 accuracy according to the Metabolomics Standards Initiative (16) (except for isoleucine) (39 increased, 9 decreased in D2 preglaucomatous retinas compared to controls). All metabolites are shown in B; significantly changed metabolites are shown in C. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) and (E) The Small Molecule Pathway Database (SMPDB) pathway analysis of metabolites demonstrates significant pathway enrichment of pathways related to glucose and pyruvate metabolism and NAD metabolism. Size of data point represents number of metabolites in pathway. (F) A schematic pathway of glycolysis integrating metabolomic and RNA-sequencing data.
Fig. 2. Retinal metabolic dysfunction occurs early following the onset of elevated IOP in D2 mice. (A) Whole retina samples underwent metabolomic profiling (at 9 mo of age, n = 10/group, control = D2-Gpnmb+, glaucoma = D2). Hierarchical clustering (HC) (Spearman’s) defined metabolically distinct groups. (B and C) A total of 86 metabolites were conclusively identified with level 1 accuracy according to the Metabolomics Standards Initiative (16) (except for isoleucine) (39 increased, 9 decreased in D2 preglaucomatous retinas compared to controls). All metabolites are shown in B; significantly changed metabolites are shown in C. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) and (E) The Small Molecule Pathway Database (SMPDB) pathway analysis of metabolites demonstrates significant pathway enrichment of pathways related to glucose and pyruvate metabolism and NAD metabolism. Size of data point represents number of metabolites in pathway. (F) A schematic pathway of glycolysis integrating metabolomic and RNA-sequencing data.CC BY-NC-ND · PubMed Central
Fig. 3. mTOR activation occurs early in glaucoma with rapamycin treatment protecting from glaucoma. (A and B) Pathway analysis of RNA-sequencing data from preglaucomatous D2 RGCs demonstrates significant enrichment of mTOR-related metabolic pathways. D2 groups 1 to 4 represent increasing disease status at the transcriptomic level as identified in Williams et al. (7). Group 1 is indistinguishable from no glaucoma controls with no significant pathway differences. (C) mTOR pathway antibody array demonstrated a specific increase in phospho-S6 and phospho-S6K, classic markers of mTOR activation. The two labels for 4E-BP1 are separate phospho sites, Thr-36 and Thr-45. (D) Phospho-mTOR (Ser-2448) increases in GCL and IPL of D2 retinas (3.5 mo control vs. 9.5 mo of age D2 shown; n = 7/group; see Materials and Methods). (E–I) Rapamycin intervention protected from optic nerve degeneration (PPD staining; n > 40/group for E, n = 10/group for axon counts and measurements in F and G) and RGC soma loss (RBPMS labeling; n = 6/group). The most common class of nerve for each group is analyzed in F and G with all being NOE except for D2 for which SEV nerves were analyzed. Control, unaffected NOE D2 nerves; D2, D2 water control; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer. *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.
Fig. 3. mTOR activation occurs early in glaucoma with rapamycin treatment protecting from glaucoma. (A and B) Pathway analysis of RNA-sequencing data from preglaucomatous D2 RGCs demonstrates significant enrichment of mTOR-related metabolic pathways. D2 groups 1 to 4 represent increasing disease status at the transcriptomic level as identified in Williams et al. (7). Group 1 is indistinguishable from no glaucoma controls with no significant pathway differences. (C) mTOR pathway antibody array demonstrated a specific increase in phospho-S6 and phospho-S6K, classic markers of mTOR activation. The two labels for 4E-BP1 are separate phospho sites, Thr-36 and Thr-45. (D) Phospho-mTOR (Ser-2448) increases in GCL and IPL of D2 retinas (3.5 mo control vs. 9.5 mo of age D2 shown; n = 7/group; see Materials and Methods). (E–I) Rapamycin intervention protected from optic nerve degeneration (PPD staining; n > 40/group for E, n = 10/group for axon counts and measurements in F and G) and RGC soma loss (RBPMS labeling; n = 6/group). The most common class of nerve for each group is analyzed in F and G with all being NOE except for D2 for which SEV nerves were analyzed. Control, unaffected NOE D2 nerves; D2, D2 water control; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer. *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 129

Metadata

Authors
Harder, J. M., Guymer, C., Wood, J. P. M., Daskalaki, E., Chidlow, G., Zhang, C., Balasubramanian, R., Cardozo, B. H., Foxworth, N. E., Deering, K. E., Ouellette, T. B., Montgomery, C., Wheelock, C. E., Casson, R. J., Williams, P. A., & John, S. W. M.
Affiliations
  • Jackson Laboratory (US)
  • The University of Adelaide (AU)
  • Karolinska Institutet (SE)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Williams, Pete A.
  • John, Simon W. M.
Venue
Proceedings of the National Academy of Sciences
Published
2020-12-14
Volume
117
Issue
52
Pages
33619-33627
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3112239941
Cited by
127
References
54
Citations by year
2026: 22 · 2025: 26 · 2024: 24 · 2023: 19 · 2022: 16 · 2021: 20
FWCI
10.90
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders
  • Vetenskapsrådet (2018-02124)
  • HHS | NIH | National Eye Institute (EY011721)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
Keywords
glaucoma, retinal ganglion cell death, intraocular pressure, glucose metabolism, pyruvate metabolism, glycolysis, mTOR signaling, rapamycin, neuroprotection, DBA/2J mice, optic nerve degeneration, glycogen mobilization
MeSH terms
Neuroprotection, Animals, Disease Models, Animal, Glaucoma, Glucose, Intraocular Pressure, Mice, Inbred C57BL, Mice, Inbred DBA, Nerve Degeneration, Retina, Rats, Sprague-Dawley, Neuroprotective Agents, Pyruvic Acid, Sirolimus, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. https://app.cochat.ai/papers/10.1073/pnas.2014213117
The paper
Harder, J. M., Guymer, C., Wood, J. P. M., Daskalaki, E., Chidlow, G., Zhang, C., Balasubramanian, R., Cardozo, B. H., Foxworth, N. E., Deering, K. E., Ouellette, T. B., Montgomery, C., Wheelock, C. E., Casson, R. J., Williams, P. A., & John, S. W. M. (2020). Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2014213117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.